4004-05-1

Basic information

• Product Name: 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE
• Synonyms: 3-SN-PHOSPHATIDYLETHANOLAMINE, 1,2-DIDEOYL;1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE;1,2-DI([CIS]-9-OCTADECENOYL)-SN-GLYCERO-3-PHOSPHOETHANOLAMINE;18:1 PE;L-ALPHA-PHOSPHATIDYLETHANOLAMINE, DIOLEOYL;L-ALPHA-PHOSPHATIDYLETHANOLAMINE, DIOLEOYL (C18:1,[CIS]-9);L-BETA,GAMMA-DIOLEOYL-ALPHA-CEPHALIN;DIOLEOYL PHOSPHATIDYL ETHANOLAMINE
• CAS NO: 4004-05-1
• Molecular Formula: C₄₁H₇₈NO₈P
• Molecular Weight: 744.03
• EINECS: 200-663-8
• Mol File: 4004-05-1.mol
• Article Data: 4

Chemical Properties

• Melting Point: 200°C(lit.)
• Boiling Point: 759.2 °C at 760 mmHg
• Flash Point: 413 °C
• Appearance: /lyophilized powder
• Density: 1.008 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.484
• Storage Temp.: −20°C
• PKA: 1.17±0.50(Predicted)
• BRN: 1718431
• CAS DataBase Reference: 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE(4004-05-1)
• EPA Substance Registry System: 1,2-DIOLEOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE(4004-05-1)

Safety Data

• Hazard Codes: Xn
• Statements: 22-38-40-48/20/22-67-36/38-20-63
• Safety Statements: 36/37-26
• RIDADR: UN 1888 6.1/PG 3
• WGK Germany: 3
• F: 8-10-23
• Hazardous Substances Data: 4004-05-1(Hazardous Substances Data)

Usage

Description

1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) is a neutral phospholipid and displays sensitivity towards pH change and has been used in the preparation of liposome and giant unilamellar vesicles (GUVs).Phosphatidylethanolamine (PE) is formed primarily in the reaction of CDP-ethanolamine and diacylglycerol. PE is one of the major components of cell membranes in bacteria and in nervous system.

Chemical Properties

Yellowish wax

Uses

Different sources of media describe the Uses of 4004-05-1 differently. You can refer to the following data:
1. 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) forms heterogenous liposomes with N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP), which are used as delivery vehicles for therapeutic agents.
2. 1,2-Dioleoyl-sn-glycero-3-phosphatidylethanolamine (DOPE) is a synthetic analog of naturally-occurring PE containing 18:1 fatty acids at the sn-1 and sn-2 positions. DOPE can be used as an emulsifier to facilitate DNA-liposome complex transport across membranes. It is used in combination with cationic phospholipids to increase efficiency during DNA transfection studies as a non-viral method of gene delivery.
3. 18:1 (Δ9-Cis) PE (DOPE) has been used in the preparation of liposome for human uncoupling protein 1 (UCP1) reconstitution and for Caenorhabditis elegans autophagy related cysteine protease protein conjugation studies. It has also been used for the generation of giant unilamellar vesicles (GUVs) for septin induced deformation studies.

Definition

ChEBI: Dioleoyl phosphatidylethanolamine is a phosphatidylethanolamine in which the phosphatidyl acyl groups are both oleoyl.

General Description

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (18:1 (Δ9-Cis) PE (DOPE)) is a neutral phospholipid and displays sensitivity towards pH change. At acidic it is an inverted hexagonal micelle and transforms to spherical micelle at alkaline pH.

Biological Activity

DOPE in mixed membranes have been found to decrease fluorescence lifetime and increase acyl-chain order. DOPE is an essential component of cationic liposomes designed to deliver DNA into gliosarcoma and kidney cell lines (gene therapy).

Biochem/physiol Actions

DOPE in mixed membranes have been found to decrease fluorescence lifetime and increase acyl-chain order. DOPE is an essential component of cationic liposomes designed to deliver DNA into gliosarcoma and kidney cell lines (gene therapy).

InChI:InChI=1/C41H78NO8P/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-40(43)47-37-39(38-49-51(45,46)48-36-35-42)50-41(44)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20,39H,3-16,21-38,42H2,1-2H3,(H,45,46)/b19-17-,20-18-/t39-/m1/s1

Synthetic route

dioleoylphosphatidylcholine (4235-95-4) + ethanolamine (141-43-5) → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
With PLD transesterification;	90%

L-1,2-Di-O-oleoyl-glycerin-3-phosphorsaeurebenzylester-<2-triphenylmethylamino-ethylester> → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
(i) NaI, (ii) aq. AcOH; Multistep reaction;

1,2-dioleoyl-sn-glycerol (24529-88-2) + ethanolamine (141-43-5) → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
With triethylamine; trichlorophosphate 1) THF, a) 0 deg C, 1 h, b) room temp., 3 h, 2) THF, a) 0 deg C, 4 h, b) room temp., 8 h; Yield given. Multistep reaction;

sodium-salt of phosphoric acid-<(R)-1,2-bis-oleoyloxy-propyl ester>-<2-phthalimido-ethyl ester> → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
With hydrazine hydrate

oleic anhydride (6085-36-5, 55726-25-5, 24909-72-6) → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
Multi-step reaction with 3 steps 1: 66 percent 2: 80 percent 3: 90 percent / PLD View Scheme

1,2-dioleoyl-sn-glycero-3-phosphate sodium salt (108392-02-5) → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: 80 percent 2: 90 percent / PLD View Scheme

(S)-3-(3,4-Dimethoxybenzyloxy)propane-1,2-diyl Dioleate (139115-88-1) → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: 84 percent / 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) / CH2Cl2; H2O / 2 h 2: 1) Et3N, POCl3, 2) Et3N / 1) THF, a) 0 deg C, 1 h, b) room temp., 3 h, 2) THF, a) 0 deg C, 4 h, b) room temp., 8 h View Scheme

L-1,2-Di-O-oleoyl-glycerin-3-phosphorsaeure-dibenzylester (19805-13-1) → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
Multi-step reaction with 3 steps 1: (i) NaI, (ii) AgNO3 2: benzene 3: (i) NaI, (ii) aq. AcOH View Scheme

L-1,2-Di-O-oleoyl-glycerin-3-phosphorsaeurebenzylester-silbersalz → 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1)

Conditions	Yield
Multi-step reaction with 2 steps 1: benzene 2: (i) NaI, (ii) aq. AcOH View Scheme

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + 3-propionic acid (80028-35-9) → C50H88N3O9P

Conditions	Yield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; Inert atmosphere;	100%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + N2-[N2,N6-bis(tert-butoxycarbonyl)-L-lysyl]-N6-(tert-butoxycarbonyl)-L-lysine (45315-76-2) → C68H126N5O16P

Conditions	Yield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In dichloromethane; N,N-dimethyl-formamide at 20℃; Inert atmosphere;	97%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + N-hydroxysuccinimidyl ester 3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclo-hexa-1,4-dienyl) butanoic acid (121030-88-4) → C55H94NO11P (1073588-75-6)

Conditions	Yield
With triethylamine In dichloromethane at 0℃; Inert atmosphere;	96%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + Propiolic acid (471-25-0) → 1,2-dioleoyl-sn-glycero-3-phosphoethanoloamine-N-prop-2'-ynamide (910227-37-1)

Conditions	Yield
With N-(3-dimethylaminopropyl)-N-ethylcarbodiimide In dichloromethane at 20℃; for 40h;	95%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + hexanedioic acid bis(N-hydroxysuccinimide ester) (59156-70-6) → DOPE-Ad-ONSu (930280-91-4)

Conditions	Yield
With triethylamine In chloroform; N,N-dimethyl-formamide at 20℃; for 2h;	95%
In chloroform; N,N-dimethyl-formamide
In chloroform; N,N-dimethyl-formamide

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + 3-(1-(1-(4-((6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11,14,17,20,23,26,29,32-decaoxa-2-azatetratriacontan-34-yl)-1H-1,2,3-triazol-4-yl)propanoic acid (1149339-80-9) → 2-(3-(1-(1-(4-((6-amino-8-hydroxy-2-(2-methoxyethoxy)-9H-purin-9-yl)methyl)phenyl)-1-oxo-5,8,11,14,17,20,23,26,29,32-decaoxa-2-azatetratriacontan-34-yl)-1H-1,2,3-triazole-4-yl)propanamido)ethyl 2,3-bis(oleoyloxy)propyl phosphate

Conditions	Yield
With 2-(1H-9-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate; triethylamine In dichloromethane; N,N-dimethyl-formamide at 20℃;	92%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + 3-(2'-acetoxy-4',6'-dimethylphenyl)-3,3-dimethylpropanoic acid (134098-68-3) → C56H96NO11P

Conditions	Yield
Stage #1: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; 3-(2'-acetoxy-4',6'-dimethylphenyl)-3,3-dimethylpropanoic acid With benzotriazol-1-ol In N,N-dimethyl-formamide at 0℃; for 0.0833333h; Inert atmosphere; Stage #2: With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃; for 5h; Inert atmosphere;	92%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + 4-{[6-amino-2-(2-methoxyethoxy)-8-oxo-7H-purine-9(8H)-yl]methyl}benzoic acid (1062444-54-5) → (2R)‑3‑(((2‑(4‑((6‑amino‑2‑(2‑methoxyethoxy)‑8‑oxo‑7,8‑dihydro‑9H-purin‑9‑yl)methyl)benzamido)ethoxy)(hydroxy)phosphoryl)oxy)propane‑1,2‑diyldioleate

Conditions	Yield
With triethylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In dichloromethane; N,N-dimethyl-formamide	79%
Stage #1: 4-{[6-amino-2-(2-methoxyethoxy)-8-oxo-7H-purine-9(8H)-yl]methyl}benzoic acid With triethylamine; HATU In N,N-dimethyl-formamide at 20℃; for 0.25h; Inert atmosphere; Stage #2: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine In dichloromethane; N,N-dimethyl-formamide for 12h; Solvent; Reagent/catalyst;

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + fluoresceinyl 5-isothiocyanate (1173-43-9) → C62H89N2O13PS

Conditions	Yield
With N-ethyl-N,N-diisopropylamine In dichloromethane at 20℃; Inert atmosphere;	79%

3-(2-((bis(benzyloxy)phosphoryl)oxy)-4,6-dimethylphenyl)-3-methylbutanoic acid (153910-64-6) + 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) → (2R)-3-(((2-(3-(2-((bis(benzyloxy)phosphoryl)oxy)-4,6-dimethylphenyl)-3-methylbutanamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate

Conditions	Yield
Stage #1: 3-(2-((bis(benzyloxy)phosphoryl)oxy)-4,6-dimethylphenyl)-3-methylbutanoic acid; 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine With benzotriazol-1-ol In N,N-dimethyl-formamide at 0℃; for 0.0833333h; Stage #2: With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide	77%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + C16H17NO6 (1073493-61-4) → C53H90NO11P (1073588-74-5)

Conditions	Yield
With triethylamine In dichloromethane at 0℃; Inert atmosphere;	75%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + N-(tert-butoxycarbonyl)-4-aminobutanoic acid (57294-38-9) → C50H93N2O11P

Conditions	Yield
With N-ethyl-N,N-diisopropylamine; HATU In chloroform; N,N-dimethyl-formamide at 20℃; Inert atmosphere;	64%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + 5-(((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl)oxy)-5-oxopentanoic acid (1415981-75-7) → (Z)-(2R)-3-(((2-(5-(((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl)oxy)-5-oxopentanamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate (1415981-76-8)

Conditions	Yield
With N-ethyl-N,N-diisopropylamine; HATU In chloroform; N,N-dimethyl-formamide at 20℃; Inert atmosphere;	61%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + (1R,8S,9ξ)-bicyclo[6.1.0]non-4-yn-9-ylmethyl (4-nitrophenyl) carbonate → (2R)-3-(((2-(((((1R,8S,9s)-bicyclo[6.1.0]non-4-yn-9-yl)methoxy)carbonyl)amino)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate

Conditions	Yield
With triethylamine In tetrahydrofuran; N,N-dimethyl-formamide at 60℃; for 6h;	60%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + 4-{[6-amino-2-(2-methoxyethoxy)-8-oxo-7H-purine-9(8H)-yl]methyl}benzoic acid (1062444-54-5) → 2-(4-((6-amino-2-(2-methoxyethoxy)-8-oxo-7H-purin-9(8H)-yl)methyl)benzamido)ethyl 2,3-bis(oleoyloxy)propyl phosphate (1346265-99-3)

Conditions	Yield
With 2-(1H-9-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluroniumhexafluorophosphate; triethylamine In dichloromethane; N,N-dimethyl-formamide at 20℃;	58%

2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetic acid + 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) → (2R)-3-((hydroxy(2-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamido)ethoxy)phosphoryl)oxy)propane-1,2-diyl dioleate

Conditions	Yield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; N-ethyl-N,N-diisopropylamine In chloroform; N,N-dimethyl-formamide at 0 - 20℃; for 6h; Inert atmosphere;	55%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + 4-methoxybenzoic acid (100-09-4) → DOPE-Anisamide

Conditions	Yield
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; for 24h; Inert atmosphere; Darkness;	51%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + PEG7 Bis-PFP ster → DOPE-PEG7-PFP

Conditions	Yield
With triethylamine In tetrahydrofuran at 20℃;	50%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + C19H16N2O6 → 3-(((2-(2-(3-benzoyl-6,7-dimethoxy-2-oxoquinoxalin-1(2H)-yl)acetamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate

Conditions	Yield
Stage #1: C19H16N2O6 With 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane; N,N-dimethyl-formamide for 0.25h; Stage #2: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine In dichloromethane; N,N-dimethyl-formamide at 20℃;	39%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + PEG-17 bis-NHS-ester → DOPE-PEG17-NHS

Conditions	Yield
With triethylamine In tetrahydrofuran at 20℃; Inert atmosphere;	36%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + all-trans-retinoic-acid (302-79-4) → (Z)-(2R)-3-(((2-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate (1415981-98-4)

Conditions	Yield
Stage #1: all-trans-retinoic-acid With diethylamino-sulfur trifluoride In diethyl ether at -78 - 20℃; Stage #2: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine With sodium carbonate In chloroform at 20℃; for 24h;	28%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + C15H21F2NO4 → C56H97F2N2O11P

Conditions	Yield
Stage #1: C15H21F2NO4 With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate In N,N-dimethyl-formamide for 0.5h; Inert atmosphere; Cooling with ice; Stage #2: 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine In tetrahydrofuran; N,N-dimethyl-formamide at 20℃; for 48h; Inert atmosphere; Cooling with ice;	20.8%

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) → 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (1069-79-0)

Conditions	Yield
With acetic acid; platinum Hydrogenation;

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + estra-1,3,5(10)-triene-3,17β-diol 17β-hemisuccinate (7698-93-3, 65684-87-9, 93939-81-2) → (Z)-Octadec-9-enoic acid (R)-2-(hydroxy-{2-[3-((13S,17S)-3-hydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yloxycarbonyl)-propionylamino]-ethoxy}-phosphoryloxy)-1-((Z)-octadec-9-enoyloxymethyl)-ethyl ester (139116-09-9)

Conditions	Yield
With benzotriazol-1-ol; dicyclohexyl-carbodiimide In dichloromethane; acetone for 5h;

1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (4004-05-1) + androst-4-en-3-one-17β-carboxylic acid (302-97-6) → C61H104NO10P (139116-00-0)

Conditions	Yield
With dmap; dicyclohexyl-carbodiimide In dichloromethane for 6h; Ambient temperature;

Upstream product

• 2442-61-7 1,2-dioleoylglycerol 
• 71260-21-4 (Z)-Octadec-9-enoic acid 1-((Z)-octadec-9-enoyloxymethyl)-2-{(2,2,2-tribromo-ethoxy)-[2-(trityl-amino)-ethoxy]-phosphoryloxy}-ethyl ester 
• 71260-68-9 (Z)-Octadec-9-enoic acid 1-((Z)-octadec-9-enoyloxymethyl)-2-[phenylamino-(2,2,2-tribromo-ethoxy)-phosphoryloxy]-ethyl ester 
• 71260-73-6 (Z)-Octadec-9-enoic acid 2-[hydroxy-(2,2,2-tribromo-ethoxy)-phosphoryloxy]-1-((Z)-octadec-9-enoyloxymethyl)-ethyl ester 
• 69747-56-4 (Z)-Octadec-9-enoic acid 2-{hydroxy-[2-(trityl-amino)-ethoxy]-phosphoryloxy}-1-((Z)-octadec-9-enoyloxymethyl)-ethyl ester 
• 19805-13-1 L-1,2-Di-O-oleoyl-glycerin-3-phosphorsaeure-dibenzylester 
• 139115-88-1 (S)-3-(3,4-Dimethoxybenzyloxy)propane-1,2-diyl Dioleate 
• 108392-02-5 1,2-dioleoyl-sn-glycero-3-phosphate sodium salt 
• 6085-36-5 oleic anhydride 
• 4235-95-4 dioleoylphosphatidylcholine 
• 141-43-5 ethanolamine 
• 24529-88-2 1,2-dioleoyl-sn-glycerol 

Downstream Products

• 139116-00-0 C₆₁H₁₀₄NO₁₀P 
• 1438280-68-2 (Z)-3-((hydroxy(2-(2-((4-oxo-3-phenyl-4,5-dihydro-3H-pyrimido[5,4-b]indol-2-yl)thio)acetamido)ethoxy)phosphoryl)oxy)propane-1,2-diyl dioleate 
• 1415981-76-8 (Z)-(2R)-3-(((2-(5-(((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-yl)oxy)-5-oxopentanamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate 
• 1415981-85-9 (Z)-(2R)-3-(((((14E,16E,18E,20E)-15,19-dimethyl-4,7,10,13-tetraoxo-21-(2,6,6-trimethylcyclohex-1-en-1-yl)-3,6,9,12-tetraazahenicosa-14,16,18,20-tetraen-1-yl)oxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate 
• 1415981-78-0 (Z)-(2R)-3-(((2-(4-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamido)butanamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate 
• 1415981-98-4 (Z)-(2R)-3-(((2-((2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenamido)ethoxy)(hydroxy)phosphoryl)oxy)propane-1,2-diyl dioleate 

Relevant articles and documents

TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR

The present invention provides, among other things, an improved method of treating cystic fibrosis (CF) in a human subject. The method comprises administering a composition comprising an mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein at a concentration of 0.5 mg/mL or greater to a human subject via nebulization. The composition is aerosolized using a nebulizer and a nominal dose of the mRNA is administered to the human subject via the nebulizer over a period of time, typically at least 30 minutes, at a suitable nebulization rate, e.g., at least 0.2 mL/minute.

Synthesis of New Phospholipids Linked to Steroid-Hormone Derivatives Designed for Two-Dimensional Crystallization of Proteins

The synthesis of phospholipids 1n-3n, rationally designed for two-dimensional crystallization of progesterone and estradiol receptors, is reported.The structure of theses lipids provides them with essential properties such as fluidity and stability when spread into monolayers at the air/H2O interface, affinity for the protein to be crystallized, and accessibility of the ligand under the lipid monolayer.